AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
3 reports, 3 independent
Updated Aug 12
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.AbbVie gained EEA approval for Boey and new products offset Humira declines.1 source
AbbVie's market success and FDA approvals drive pipeline growth amid Fed caution.1 source
Keep exploring
The entities involved
Related events
- Biosimilar erosion is impacting market share, and AbbVie, Procter & Gamble, and Johnson & Johnson are noted as major consumer goods players.
- MarketBeat provided analyst ratings for Alvotech, a company developing a biosimilar to Humira.
- AbbVie is listed on the Nasdaq stock exchange, and MarketBeat is reporting on its stock performance.
- FDA approval enables commercial opportunity involving CBRE Group.